1stOncology™: Cancer Intelligence Service – Page 9988 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021 Annual Meeting

On February 3, 2021 Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, reported that data from non-human primate studies of the company’s proprietary fully human Interleukin 12 (IL-12) therapeutic candidate, SON-1010, will be presented at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting 2021, April 10-15 and May 17-21 (Press release, Sonnet BioTherapeutics, FEB 3, 2021, View Source [SID1234576688]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Details of the abstract and poster presentation are as follows:

Title: Toxicity profile of interleukin 12 attached to a fully human albumin binding domain (FHABTM) in Cynomolgus macaques
Abstract Number: 1589
Session: Combination Immunotherapies
Presentation Type: E-poster
Date: Available for browsing on April 10, 2021 through June 21, 2012

Leidos To Participate In The Cowen 42nd Annual Aerospace/Defense & Industrials Conference

On February 3, 2021 Leidos (NYSE: LDOS), a FORTUNE 500 science and technology company, reported that it will participate in the Cowen 42nd Annual Aerospace/Defense & Industrials Conference webcast (Press release, Leidos, FEB 3, 2021, View Source;Industrials-Conference/default.aspx [SID1234574999]).

Roger Krone, Chief Executive Officer, will participate in a question and answer "fireside chat" on Thursday, February 11, 2021 at 11:00am ET.

A live audio webcast of the event will be available on the Leidos Investor Relations website at View Source A replay of the webcast will be available following the presentation at the same link listed above for 90 days afterward.

InnoCare Brings On Hillhouse as Strategic Investor, Vivo Capital Increases Holdings

On February 3, 2021 InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, reported two subscription agreements with Gaoling and YHG, a company of Hillhouse Capital Group, and Vivo Opportunity Fund, L.P, a company of Vivo Capital VIII, LLC (Press release, InnoCare Pharma, FEB 3, 2021, View Source [SID1234574706]). The two investors subscribed 191,613,000 and 18,895,000 new shares respectively, for a total of 210,508,000 new Shares, representing about 16.33% of the existing total issued Shares of the Company as at the date of this announcement and approximately 14.04% of the total issued Shares of the Company as enlarged by the allotment and issue of the Subscription Shares. The subscription price of HK$14.45 per share represents an 8.32% premium to the average closing price of the five trading days immediately preceding the date of the Subscription Agreements (not including 2 February 2021).

Hillhouse Capital has adhered to the philosophy of value investment, and Vivo Capital focuses on investing in high-quality companies in the fields of life science and healthcare. The two investors are fully in line with InnoCare’s core value of "Science Drives Innovation".

InnoCare has built an integrated new drug development platform and continues to build a more competitive product pipeline. In addition to the self-developed Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib, which was approved for marketing at the end of last year, InnoCare has developed over a balanced pipeline of 10 drug candidates for the treatment of malignant tumors and autoimmune diseases. For example, the company’s pan-FGFR inhibitor ICP-192, which is currently in being studied two phase II clinical trials for the treatment of cholangiocarcinoma and urothelial carcinoma in China, has shown promising early efficacy data in patients with FGFR gene alterations. At the same time, InnoCare is also conducting phase I clinical trials of ICP-192 in the United States. Second-generation pan-TRK inhibitor ICP-723 is in phase I clinical trials in China for the treatment of advanced or metastatic solid tumors carrying NTRK fusion genes, which include indications such as breast cancer, colorectal cancer, lung cancer, thyroid cancer, etc., as well as patients who are resistant to the first generation of TRK inhibitors. In addition, InnoCare has been conducting multi-center and multi-indication clinical trials of orelabrutinib in China and the United States, including a global phase II clinical trial for the treatment of multiple sclerosis.

Based on the long-term investments, Hillhouse Capital has attached great importance to the biotech sector and values company’s long-term growth capabilities. The strategic investment from Hillhouse demonstrated the recognition of InnoCare’s strong innovation capabilities.

As one of InnoCare’s early and cornerstone investors, Vivo Capital has shared many experiences and resources with InnoCare, helping the company become a leader in the innovative drug field.

Dr. Jasmine Cui, the co-founder, Chairwoman and CEO of InnoCare said, "I am very pleased that Hillhouse Capital has joined as a strategic investor. At the same time, Vivo Capital has increased its holdings. The biotech industry needs continuous innovation and capital support. We believe that, through our joint efforts, InnoCare will develop more high-quality innovative drugs to benefit patients in China and around the world."

Sana Announces Upsized Pricing of Initial Public Offering

On February 3, 2021 Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, reported the pricing of its upsized initial public offering of 23,500,000 shares of its common stock at a public offering price of $25.00 per share (Press release, Sana Biotechnology, FEB 3, 2021, View Source [SID1234574702]). All of the shares of common stock are being offered by Sana. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sana, are expected to be $587.5 million. Sana’s common stock is expected to begin trading on The Nasdaq Global Select Market on February 4, 2021, under the ticker symbol "SANA." The offering is expected to close on February 8, 2021, subject to the satisfaction of customary closing conditions. In addition, Sana has granted the underwriters a 30-day option to purchase up to an additional 3,525,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions, and, if exercised in full, would result in aggregate gross proceeds of approximately $675.6 million.

Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint book-running managers for the offering.

Registration statements relating to the shares being sold in this offering were filed with the Securities and Exchange Commission and became effective on February 3, 2021. The offering is being made only by means of a prospectus, copies of which may be obtained, when available, from: Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at [email protected]; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at [email protected], or by telephone at (866) 803-9204; or BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering

On February 3, 2021 Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, reported the pricing of its upsized initial public offering of 7,000,052 shares of common stock at a public offering price of $19.00 per share (Press release, Sensei Biotherapeutics, FEB 3, 2021, View Source [SID1234574674]). The gross proceeds to Sensei from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sensei, are expected to be approximately $133.0 million. All of the shares are being offered by Sensei and are expected to begin trading on The Nasdaq Global Market on February 4, 2021 under the ticker symbol "SNSE." In addition, Sensei has granted the underwriters a 30-day option to purchase up to an additional 1,050,007 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on February 8, 2021 subject to the satisfaction of customary closing conditions.

Citigroup, Piper Sandler & Co. and Berenberg are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as the lead manager for the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

A registration statement relating to the securities was declared effective by the Securities and Exchange Commission on February 3, 2021. The offering of these securities is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 800-831-9146 or by email at [email protected]; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924 or by email at [email protected]; or Berenberg Capital Markets LLC, Attention: Investment Banking, 1251 Avenue of the Americas, 53rd Floor, New York, NY 10020, or by telephone at 646-949-9000 or by email at [email protected].

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.